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A B S T R A C T
Hyperfiltration has been documented in type 1 diabetes and may contribute to the high risk for development of albu-
minuria and progression of nephropathy. However, recent studies suggest that the risk of progression to albuminuria in
type 1 diabetes was not increased by hyperfiltration. We investigated associations of estimated glomerular filtration rate
(eGFR) and urinary albumin excretion rate (UAE) in normoalbuminuric type 1 diabetic patients. Study included 313
normoalbuminuric patients with type 1 diabetes, none showed signs of adrenal, renal, or cardiovascular diseases. GFR
was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. Glomerular hyper-
filtration was defined as eGFR ³ 125 mL min–1 1.73 m–2. Renal hyperfiltration was present in 12% of the study group.
Subjects with eGFR ³ 125 mL min–1 1.73 m–2 were younger, had shorter duration of diabetes, lower levels of total and
LDL cholesterol, and higher HbA1c than subjects with an eGFR below 125 mL min–1 1.73 m–2. Type 1 diabetic patients
with hyperfiltration also had significantly lower UAE. In a multiple logistic regression analysis, higher eGFR was asso-
ciated with lower UAE. Our results indicate that normoalbuminuric type 1 diabetic patients with hyperfiltration have
lower UAE than those with renal function in the normal range. Together with other recent studies this may suggest that
creatinine-based estimates of GFR indicating hyperfiltration is not associated with higher UAE and subsequent develop-
ment of microalbuminuria.
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Introduction
Long-standing type 1 diabetes is characterized by a
decline in glomerular filtration rate (GFR) in contrast to
general population, but in early stages of diabetes hyper-
filtration is characteristic1. The prevalence of hyper-
filtration in type 1 diabetes varies from less than 25% to
more than 75%2. Studies in type 1 diabetes showed that
primary increases in proximal tubular sodium resorption
lead to glomerular hyperfiltration3. Glomerular hyper-
filtration is usually promoted by hyperglycaemia, and re-
duction of blood glucose with insulin therapy returns glo-
merular hyperfiltration to near normal levels4.
Hyperfiltration has been suggested as a risk factor for
the development of albuminuria and progressive nephro-
pathy, and hyperfiltration usually precedes changes in
albuminuria by several years2,5,6. It was also suggested
that hyperfiltration predicts the development of renal ul-
tra-structural changes2,7. A meta-analysis of ten cohort
studies of 780 normoalbuminuric patients showed that
progression to micro and macroalbuminuria was signifi-
cantly higher in patients with hyperfiltration at base-
line8. In a single-centre study of 426 normoalbuminuric
patients with a follow-up of 5, 10 and 15 years the risk of
progression to microalbuminuria was not increased by
hyperfiltration9. Moreover, a recent prospective study in-
cluding 2,318 normoalbuminuric type 1 diabetic patients
found that the distribution of estimated glomerular fil-
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tration rate (eGFR) in adults normoalbuminuric type 1
diabetic patients was not significantly different from
general population10. In addition, type 1 diabetic patients
with a higher eGFR were also no more likely to develop
microalbuminuria over a median of 5.2 years of follow-up
than those with normal eGFR.
The aim of this study was to explore the relationship
between eGFR and urinary albumin excretion rate
(UAE) in normoalbuminuric type 1 diabetic patients
with normal renal function.
Subjects, Materials and Methods
This study included 313 normoalbuminuric patients
with diabetes mellitus type 1. Type 1 diabetes was de-
fined as an onset of diabetes before the age of 35 years,
positive autoantibodies and permanent insulin treat-
ment initiated within 1 year of diagnosis. Subjects with
insulin-treated diabetes secondary to other pathologies
were excluded. The study included patients following
characteristics: age of 18–65 years, minimum duration of
type 1 diabetes of 1 year, no medical history of disorders
of adrenal gland function, cardiovascular diseases or
electrocardiogram (ECG) evidence of ischemic heart dis-
ease, absence of any systemic disease, and absence of any
infections in the previous months. Patients with chronic
renal disease or other chronic diseases likely to affect re-
nal function were excluded. Patients were excluded from
the study if they had taken any of the following: lipid-
-lowering therapy, ACE inhibitors or angiotensin II re-
ceptor blockers, medications that might affect glucose
metabolism such as glucocorticoids as well as patients
taking oral glucose-lowering medication. Acute and chro-
nic inflammation was excluded on the basis of medical
history, physical examination, and routine laboratory
tests, including measurement of temperature and urinal-
ysis.
All subjects were studied in the morning after an
overnight fast. Basic anthropometric measurements we-
re performed on all study subjects. UAE was measured
from at least two 24-h urine samples and determined as
the mean of 24-h urine collections. Patients performed
collections on two consecutive days to minimize variabil-
ity. Normoalbuminuria was defined as a UAE<30 mg/
24h. Those with microalbuminuria (UAE³30<300 mg/
24h) and macroalbuminuria (UAE³300 mg/24h) were ex-
cluded from the study. Serum creatinine was measured
in fasting blood sample. From 2011 creatinine was mea-
sured by an enzymatic method that produced values
traceable to the isotope dilution mass spectrometry
(IDMS) values. We calibrated creatinine results gener-
ated before 2011 to the IDMS-traceable values obtained
with the enzymatic method. Data on serum creatinine
levels, age, sex and race were used to calculate the eGFR
using the Chronic Kidney Disease Epidemiology Collabo-
ration (CKD-EPI) formula, which has been shown to be
accurate in determining renal function in diabetic pa-
tients with normal renal function. GFR was also esti-
mated using the 175 Modification of Diet in Renal Dis-
ease and the Cockcroft and Gault formula. Glomerular
hyperfiltration was defined as eGFR ³ 125 mLmin–1 1.73
m–2. Those with impaired eGFR (less than 60 mL min–1
1.73 m–2) were excluded from the study.
Microalbumin and HbA1c were measured spectropho-
tometrically by turbidimetric immuno-inhibition (Olym-
pus AU600, Beckman-Coulter, USA). Results of HbA1c
(%) are expressed in the DCCT-equivalent. Complete
blood count was determined on an automatic blood coun-
ter (Advia 120, Siemens Diagnostic Solutions, USA).
The study protocol complies with the Declaration of
Helsinki as well as with local institutional guidelines,
and was approved by the local ethnics committees.
Data are expressed as means ± SD for normally dis-
tributed values, as median with range for non-normally
distributed values, and percentage. Correlations between
parameters of renal function with anthropometric and
metabolic variables were determined using Spearman
rho test. To investigate the relation between eGFR with
UAE and other parameters data were also stratified ac-
cording to levels of GFR estimated using the CKD-EPI
formula and quartiles of UAE. Kruskal-Wallis test was
used for calculating the significance of the trend for each
variable among quartiles of UAE and among hyperfil-
trating patients and those with normal renal function.
Multiple logistic regression analysis was used to assess
associations of eGFR with risk of higher UAE. Level of
statistical significance was chosen to a=0.05. Statistical
analysis was performed by statistical package STATA/IC
ver.11.1.
Results
The characteristics of the study subjects are listed in
Table 1. The average age was approximately 34 years,
most were not overweight and 51% of subjects were fe-
male. Mean/median values of BMI, waist to hip ratio
(WHR), systolic and diastolic blood pressure, HDL cho-
lesterol, and triglycerides were within the normal range
for patients with diabetes with slightly elevated levels of
HbA1c, total and LDL cholesterol. In individuals with
normoalbuminuria, the mean GFR estimated by the
CKD-EPI was 106 mL min–1 1.73 m–2. Using the CKD-
-EPI formula 12% of patients had an eGFR ³ 125 mL
min–1 1.73 m–2. Renal function estimated using the
MDRD formula was significantly lower (98 mL min–1
1.73 m–2) than when estimated using the CKD-EPI for-
mula. However, the number of patients with an eGFR ³
125 mL min–1 1.73 m–2 was similar to that found with the
CKD-EPI formula. The mean eGFR using Cockcroft-
-Gault formula was 101 mL min–1 1.73 m–2, and 59 pa-
tients (19%) had eGFR ³ 125 mL min–1 1.73 m–2, more
than with others formula, which is in accordance with
previous studies10.
Characteristics of study subjects with and without re-
nal hyperfiltration are displayed in Table 2. Subjects
with eGFR ³ 125 mL min–1 1.73 m–2 were younger, had
shorter duration of diabetes, lower levels of total and
LDL cholesterol, and higher HbA1c than subjects with
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an estimated GFR below 125 mL min–1 1.73 m–2. How-
ever, blood pressure, HDL cholesterol, triglycerides, BMI
and WHR were similar among those with and without
hyperfiltration. In addition, hyperfiltration status did
not significantly differ between males and females (11.4
vs. 13.0 %), or between smokers and non-smokers (11.8
vs. 12.7 %). Surprisingly, UAE was significantly lower in
subjects with eGFR ³ 125 mL min–1 1.73 m–2, than in
subjects with eGFR 60–124 mL min–1 1.73 m–2.
Associations of renal parameters with anthropome-
tric and metabolic variables are presented in Table 3.
UAE was significantly associated with duration of diabe-
tes, HDL cholesterol, triglycerides and diastolic blood
pressure, with diastolic blood pressure showing the stron-
gest correlation (r=0.23). In addition, serum creatinine
was significantly associated with BMI, WHR, HbA1c,
HDL cholesterol and systolic blood pressure, with WHR
showing the strongest correlation (r=0.39). Estimated
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TABLE 2
CLINICAL AND METABOLIC CHARACTERISTICS OF PATIENTS DEPENDING ON LEVEL OF eGFR
(ESTIMATED WITH THE CKD-EPI FORMULA)
Variable eGFR 60–89
eGFR 90–124
mL min–1 1.73 m–2
eGFR ³125 p
N 55/313 220/313 38/313
Sex (m/f) 19/36 116/104 17/21 0.04
Age (years) 45 (19–60) 35 (19–65) 22 (18–34) <0.001
Duration of diabetes (years) 16 (2–42) 12 (1–42) 7 (1–25) <0.001
Body mass index (kg/m2) 24 (17–33) 24 (17–37) 24 (15–34) 0.4
Waist to hip ratio 0.81±0.07 0.81±0.06 0.81±0.06 0.7
HbA1c (%) 7.1±1.2 7.3±1.6 8.4±1.9 0.002
Systolic blood pressure (mmHg) 120 (79–170) 120 (90–180) 120 (90–140) 0.3
Diastolic blood pressure (mmHg) 80 (65–110) 80 (60–110) 80 (50–90) 0.7
Total cholesterol (mmol/L) 5.1±0.7 5.0±0.9 4.6±0.7 0.02
LDL cholesterol (mmol/L) 2.9±0.7 2.8±0.7 2.4±0.7 0.006
HDL cholesterol (mmol/L) 1.8±0.4 1.6±0.3 1.6±0.3 0.1
Triglycerides (mmol/L) 0.91 (0.4–2.5) 0.8 (0.3–4.1) 0.95 (0.4–4.1) 0.3
Serum creatinine (mmol/L) 86±14 70±11 56±10 <0.001
Urinary albumin excretion (mg/24h) 13.7 (1.7–29.4) 10.8 (2.2–29.8) 7.0 (2.7–29.8) <0.001
TABLE 1
CLINICAL AND METABOLIC CHARACTERISTICS OF
ALL PATIENTS
Variable Value
Age (years) 34 (18–65)
Duration of diabetes (years) 12 (1–42)
Body mass index (kg/m2) 24 (15–37)
Waist to hip ratio 0.81±0.07
HbA1c (%) 7.43±1.63
Systolic blood pressure (mmHg) 120 (79–180)
Diastolic blood pressure (mmHg) 80 (50–100)
Total cholesterol (mmol/L) 5.0±0.8
LDL cholesterol (mmol/L) 2.8±0.7
HDL cholesterol (mmol/L) 1.7±0.4
Triglycerides (mmol/L) 0.91 (0.3–4.1)
Serum creatinine (mmol/L) 71±14
CKD-EPI (mL min–1 1.73 m–2) 106±16
MDRD (mL min–1 1.73 m–2) 98±20
Cockcroft-Gault (mL min–1 1.73 m–2) 101±28
Urinary albumin excretion (mg/24h) 11.0 (1.7–29.8)
CKD-EPI – Chronic Kidney Disease Epidemiology Collabora-
tion, MDRD – Modification of Diet in Renal Disease.
TABLE 3
SPEARMAN CORRELATION ANALYSIS OF ASSOCIATIONS
OF RENAL PARAMETERS WITH METABOLIC AND
ANTHROPOMETRIC VARIABLES
Variable UAE
Serum
creatinine
eGFR
Age 0.07 0.02 –0.60*
Duration of diabetes 0.14* 0.00 –0.29*
Body mass index –0.02 0.15* –0.10
Waist to hip ratio 0.01 0.39* 0.01
HbA1c 0.06 –0.14* 0.15*
Total cholesterol 0.02 –0.01 –0.21*
LDL cholesterol 0.03 0.08 –0.18*
HDL cholesterol –0.13* –0.19* –0.17*
Triglycerides 0.11* 0.07 0.06
Systolic blood pressure 0.09 0.11* –0.08
Diastolic blood pressure 0.23* 0.08 –0.01
*p<0.05, UAE – urinary albumin excretion rate, eGFR – esti-
mated glomerular filtration rate.
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GFR using CKD-EPI formula significantly correlated
with even 6 parameters (age, duration of diabetes, HbA1c,
total, LDL and HDL cholesterol). The magnitude of
these associations were strongest for age and duration of
diabetes (r= –0.60, and –0.29, respectively, all p<0.001).
Relationship between eGFR among those in the 2nd,
3rd and 4th quartiles of UAE compared to those in quar-
tile 1 are presented in table 4. Stratifying eGFR for de-
gree of UAE trends across quartiles for GFR estimated
by CKD-EPI, MDRD and Cockcroft-Gault formula were
not statistically significant, but subjects in the 1st quar-
tile of UAE had elevated eGFR levels compared to sub-
jects in 2nd, 3rd and 4th quartiles.
In logistic regression analysis, lower estimated GFR
calculated using CKD-EPI and Cockroft-Gault formula
was significantly associated with risk of higher UAE
(OR=0.98–0.99) (Table 5, Model A). However, after ad-
justment for age, sex, duration of diabetes and BMI only
eGFR assessed by Cockcroft-Gault was associated with
higher UAE in our normoalbuminuric subjects (Table 5,
Model B).
Discussion
Hyperfiltration has been suggested as a risk factor for
the development of albuminuria and progressive nephro-
pathy, and hyperfiltration usually precedes changes in
albuminuria by several years2,5,6. However, recent stud-
ies suggest that the risk of progression to albuminuria in
type 1 diabetes was not increased by hyperfiltration6,9–11.
In support to this data, we showed that elevated eGFR in
normoalbuminuric type 1 diabetic patients is not associ-
ated with higher UAE. Moreover, in logistic regression
analysis higher eGFR tended to be associated with lower
UAE. In addition, mean values of UAE of 7 mg/24h in our
hyperfiltrating patients is not an early predictive factor
for the delopment of albuminuria12,13. Taken together
with other studies9,10, it seems that creatinine-based esti-
mates of GFR is not associated with higher UAE and sub-
sequent development of microalbuminuria.
The prevalence of hyperfiltration in type 1 diabetes
varies from less than 25% to more than 75%2,14, and
those subjects display increased mortality independent
of presence or severity of albuminuria15. It is more often
in patients with newly diagnosed diabetes, which is rap-
idly normalized by intensive insulin treatment16. Preva-
lence of hyperfiltration in our subjects was only 12%,
probably because creatinine-based methods tend to un-
derestimate GFR in the hyperfiltration range2. However,
recent prospective study including 2,318 initially nor-
moalbuminuric type 1 diabetic patients found that the
distribution of eGFR in adults normoalbuminuric type 1
diabetic patients was not significantly different from
general population10.
It has been argued that in type 1 diabetes uncon-
trolled hyperglycemia is the most important determinant
of hyperfiltration, and subsequent progressive kidney
disease2,8. Moreover, it was showed that hyperglycemia is
associated with higher GFR in hyperfiltering type 1 dia-
betic patients, with no change in GFR in normofiltering
diabetics or in normal control subjects17. However, early
hyperfiltration can be reversed by insulin therapy and
better glucoregulation16,18. In contrast, persistent hyper-
filtration may persist for years and may not be associated
with glycemic control assessed by HbA1c2. In our study
mean HbA1c levels (7.4%) was significantly lower than
in most previous studies. Glycaemic control was associ-
ated with eGFR, such that subjects with higher levels of
HbA1c had higher eGFR. In addition, poor glycemic con-
trol was associated with an increased incidence of micro-
albuminuria10,19, and lower A1c with returning to normo-
albuminuria from microalbuminuria20,21. In our study,
hyperfiltrating subjects had significantly higher HbA1c
levels, but lower UAE. It is possible that reduction of
plasma glucose levels in our patients caused GFR to be-
come normal in initially hyperfiltrating patients, which
is previously observed4,16.
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TABLE 4
QUARTILES OF URINARY ALBUMIN EXCRETION RATE
1st quartile
<6.8 mg/24h
2nd quartile
6.8–10.9
3rd quartile
11.0–16.7
4th quartile
>16.7 mg/24h
p
for trend
CKD–EPI 110±16 106±14 103±15 105±18 0.08
MDRD 103±22 96±18 94±17 97±23 0.06
Cockcroft-Gault 110±34 99±26 100±23 96±25 0.08
CKD-EPI – Chronic Kidney Disease Epidemiology Collaboration, MDRD – Modification of Diet in Renal Disease
TABLE 5
MULTIVARIATE LOGISTIC REGRESSION ANALYSIS OF eGFR
WITH DEVELOPMENT OF HIGHER URINARY ALBUMIN
EXCRETION RATE
Independent
variable
Model A Model B
CKD-EPI 0.98 (0.97-0.99)* 0.98 (0.96–1.00)
MDRD 0.99 (0.97–1.00) 0.98 (0.97–1.00)
Cockcroft-Gault 0.99 (0.98–0.99)* 0.98 (0.97–0.99)*
Data are OR (95% CI) from separate models. Model A crude,
model B adjusted for age, sex, duration of diabetes, BMI.
*p<0.05. CKD-EPI – Chronic Kidney Disease Epidemiology Col-
laboration, MDRD – Modification of Diet in Renal Disease.
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It was shown that the incidence of microalbuminuria
was also associated with serum lipids22,23. Serum lipids
were associated with eGFR and UAE in our subjects.
However, those subjects with eGFR ³ 125 mL min–1 1.73
m–2 had significantly lower levels of total and LDL cho-
lesterol. It is possible that better lipid profile in our
hyperfiltrating subjects may be explanation of the lack of
association between hyperfiltration and higher UAE ob-
served by us.
Since we investigated adult type 1 diabetic patients, it
is also possible that hyperfiltration in type 1 diabetes is a
childhood or early adult phenomenon20. In subjects with
longer duration of diabetes, progression to higher UAE
was associated with a GFR below 100 mL min–1 1.73 m–2
24,25. We were unable to assess the effect of hyperfiltra-
tion occurring and resolving very soon after diabetes on-
set because the majority of our patients have over 5 years
duration of diabetes. It is possible that renal hyperfil-
tration has an impact on higher UAE in early duration of
diabetes, and our patients with longer duration of diabe-
tes and initially hyperfiltration may have returned to
normal filtration levels. Moreover, our patients were in-
vestigated years after exposure to pubertal hormonal
changes, which are thought to increase hyperfiltration21.
Additionally, there is a normal physiological decline in
GFR associated with ageing. However, in previous pro-
spective studies observing the increase of UAE in hyper-
filtrating patients, the baseline UAE did not differ or
were higher according to hyperfiltration status6,13,21,26,27.
Moreover, lower baseline UAE was predictive of regres-
sion of microalbuminuria28. In addition, higher UAE val-
ues in the normoalbuminuric range were predictors of
progression to microalbuminuria or proteinuria13,29,30.
The present study has a number of potential limita-
tions. First, our study was cross-sectional, which limited
our ability to infer a causal relation between hyperfiltra-
tion and risk for the development of microalbuminuria.
Second, our analyses were based on measurement of
eGFR and UAE on two consecutive days that may not re-
flect the relation over time. Third, creatinine-based for-
mula used to estimate GFR is not the »gold standard«
procedure and tend to underestimate GFR in the hyper-
filtration range, while Cockcroft-Gault formula overesti-
mates the actual renal function.
In summary, our results indicate that normoalbu-
minuric type 1 diabetic patients with hyperfiltration
have lower UAE than those with renal function in the
normal range. Together with other recent studies this
may suggest that creatinine-based estimates of GFR in-
dicating hyperfiltration is not associated with higher
UAE and subsequent development of microalbuminuria.
However, future studies will need to address the inde-
pendent role of hyperfiltration in the evolution of al-
buminuria in type 1 diabetes.
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UTJECAJ HIPERFILTRACIJE NA RAZINU ALBUMINA U URINU U NORMOALBUMINURI^NIH
BOLESNIKA S TIPOM 1 [E]ERNE BOLESTI
S A @ E T A K
Glomerularna hiperfiltracija je ~esta kod bolesnika s tipom 1 {e}erne bolesti i dugi niz godina je prepoznata kao
rizi~ni ~imbenik razvoja mikro- i makroalbuminurije te nefropatije. Me|utim, novije prospektivne studije na velikom
broju ispitanika s tipom 1 {e}erne bolesti nisu potvrdile da hiperfiltracija doprinosi razvoju mikroalbuminurije. Istra-
`ivali smo povezanost glomerularne filtracije (GF) i razine albumina u urinu u normoalbuminuri~nih bolesnika s tipom
1 {e}erne bolesti. U istra`ivanje je uklju~eno 313 bolesnika s tipom 1 {e}erne bolesti koji nisu imali poreme}aj funkcije
nadbubre`ne `lijezde, bubre`nu insuficijenciju ili kardiovaskularnu bolest. GF je izra~unata prema Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) formuli. Glomerularna hiperfiltracija je definirana kao vrijednost GF ³
125 mL min–1 1,73 m–2. Glomerularna hiperfiltracija je bila prisutna u 12% ispitanika. Ispitanici s GF ³ 125 mL min–1
1,73 m–2 bili su mla|i, imali su kra}e trajanje {e}erne bolesti, ni`u razinu ukupnog i LDL kolesterola te vi{u razinu
HbA1c u odnosu na ispitanike s GF <125 mL min–1 1,73 m–2. Bolesnici s glomerularnom hiperfiltracijom su imali
statisti~ki zna~ano ni`u razinu albumina u urinu. Multiplom logisti~kom regresijom vi{a vrijednost GF bila je povezana
s ni`om razinom albumina u urinu. Rezultati na{eg istra`ivanja ukazuju da je serumskim kreatininom izra~unata
glomerularna hiperfiltracija povezana s ni`om razinom albumina u urinu u normoalbuminuri~nih bolesnika s tipom 1
{e}erne bolesti. Rezultati na{eg istra`ivanja su u skladu s rezultatima novijih istra`ivanja koji ukazuju da glomeru-
larna hiperfiltracija nije rizi~ni ~imbenik kasnijeg razvoja mikroalbuminurije u bolesnika s tipom 1 {e}erne bolesti.
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